I-Mab IMAB:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 3:30 PM EDT
1.80UNCH (UNCH)
Volume
291,724
52 week range
1.16 - 3.45
Loading...
  • Open1.80
  • Day High1.85
  • Day Low1.79
  • Prev Close1.80
  • 52 Week High3.45
  • 52 Week High Date05/16/23
  • 52 Week Low1.16
  • 52 Week Low Date09/25/23

Key Stats

  • Market Cap145.263M
  • Shares Out80.70M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta1.09
  • YTD % Change-5.26

KEY STATS

  • Open1.80
  • Day High1.85
  • Day Low1.79
  • Prev Close1.80
  • 52 Week High3.45
  • 52 Week High Date05/16/23
  • 52 Week Low1.16
  • 52 Week Low Date09/25/23
  • Market Cap145.263M
  • Shares Out80.70M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta1.09
  • YTD % Change-5.26

RATIOS/PROFITABILITY

  • EPS (TTM)-2.28
  • P/E (TTM)-0.79
  • Fwd P/E (NTM)-0.76
  • EBITDA (TTM)-170.763M
  • ROE (TTM)-63.34%
  • Revenue (TTM)3.819M
  • Gross Margin (TTM)100.00%
  • Net Margin (TTM)-5,302.03%
  • Debt To Equity (MRQ)1.74%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On I-Mab

 

Profile

MORE
I-Mab is a global biotech company. The Company is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Company’s pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against...
Pamela Klein M.D.
Interim Independent Chairman of the Board
Rajkumar Kannan
Chief Executive Officer, Director
Joseph Skelton
Chief Financial Officer
Weimin Tang Ph.D.
Executive Vice President, Chief Business Officer
Address
Suite 400, 2440 Research Blvd
Rockville, MD
20850
United States